摘要
目的为全面了解临床医生管理化疗相关性贫血(CIA)的现状与观念,分析目前CIA治疗领域存在的问题,启动肿瘤临床医生关于CIA诊治及管理现状的调查。方法2024年1月至2024年5月期间,甘肃省肿瘤医院面向不同层级医疗机构的临床医生发起“肿瘤化疗相关性贫血调研”线上问卷。评估CIA对肿瘤治疗的影响、CIA的临床实践措施及目标、抗体偶联药物(ADC)相关CIA管理、医生获取CIA前沿信息的途径等信息。结果共收集了308份线上调研问卷,覆盖28个省、自治区、直辖市的204家医院,其中127家(62%)为三甲医院。研究发现,参与调研的医生在过去3个月中处方化疗方案患者CIA发生人次为10(3,30)人次,贫血导致化疗剂量减少或化疗延迟的发生率为22%。调研结果显示,仅33%的医生认为需尽早治疗CIA,即当血红蛋白(Hb)≤100 g/L时,及时纠正贫血;40%的医生在临床实践中,仍以Hb≤80 g/L为治疗CIA的启始时机。71%的医生认为化疗期间应将Hb水平维持在90~110 g/L范围。对于ADC引起的贫血,49%的医生认为当Hb≤80 g/L时需要治疗。结论CIA治疗领域存在起始治疗时机过晚、治疗靶目标较低、对CIA的影响及危害认识不足等问题,可能与临床治疗贫血手段有限相关。
Objective A nationwide survey on the diagnosis,treatment,and management of chemotherapy-induced anemia(CIA)among Chinese oncology clinical doctors has been initiated in order to study the issues in the field of CIA treatment and to gain a thorough understanding of the current state and concept of CIA management among Chinese clinical doctors.Methods The"Chemotherapy-induced Anemia Survey"was an online survey of Gansu Provincial Cancer Hospital that was made available to clinical physicians from various levels of medical institutions nationwide between January and May 2024.CIA's effects on tumor treatment,clinical practice measures and objectives,CIA management of antibody drug conjugates(ADCs),and methods for physicians to access the most recent CIA information were all assessed.Results The median and quartile incidence of CIA in patients prescribed chemotherapy regimens in the past 3 months among the physicians participating in the study was 10(3,30),and anemia-related chemotherapy dose delay/reduction(DDR)occurred in 22%of cases.Only 33%of physicians,according to the survey's results,think that CIA should be treated as soon as possible,meaning that anemia should be treated promptly when hemoglobin(Hb)≤100 g/L.In clinical practice,40%of physicians stll start treating CIA when Hb≤80 g/L.During chemotherapy,71%of physicians thought that the Hb level should be kept between 90-110 g/L.49%of physicians thought that treatment was necessary for ADC-induced anemia when Hb≤80 g/L.
作者
罗旭
张悦
舒棣添
容启翔
田迎霞
史艳侠
LUO Xu;ZHANG Yue;SHU Di-tian;RONG Qi-xiang;TIAN Ying-xia;SHI Yan-xia(Department of Breast Oncology,Sun Yat-sen University Cancer Center Gansu Hospital/Gansu Provincial Cancer Hospital,Lanzhou 730050,China;不详)
出处
《中国实用内科杂志》
北大核心
2025年第4期308-314,共7页
Chinese Journal of Practical Internal Medicine
基金
国家自然科学基金(82073391,82060535)
兰州市科技发展指导性计划项目(2023-ZD-68,2019-ZD-137)。
